Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACGNNASDAQ:ATHANASDAQ:BCDANYSE:CHRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACGNAceragen$0.38$0.46$0.36▼$16.00N/AN/AN/AN/AATHAAthira Pharma$0.30+2.4%$0.29$0.22▼$3.67$11.52M3.031.58 million shs37,987 shsBCDABioCardia$1.95-9.3%$2.28$1.63▼$4.66$11.13M0.83262,805 shs75,679 shsCHROChromocell Therapeutics$1.26-6.7%$1.15$0.45▼$3.80$8.31M3.27446,134 shs297,097 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACGNAceragen0.00%0.00%0.00%0.00%0.00%ATHAAthira Pharma0.00%-2.64%-2.22%+5.36%-88.87%BCDABioCardia0.00%+3.37%-0.46%-15.35%-27.61%CHROChromocell Therapeutics0.00%+17.39%+45.88%-3.36%+2.27%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACGNAceragenN/AN/AN/AN/AN/AN/AN/AN/AATHAAthira Pharma2.8908 of 5 stars3.03.00.00.03.21.71.3BCDABioCardia3.7618 of 5 stars3.85.00.00.03.02.50.6CHROChromocell Therapeutics0.4854 of 5 stars0.04.00.00.00.02.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACGNAceragen 0.00N/AN/AN/AATHAAthira Pharma 2.00Hold$11.253,625.17% UpsideBCDABioCardia 3.50Strong Buy$25.001,182.05% UpsideCHROChromocell Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACGNAceragen$4.86M0.66N/AN/AN/A∞ATHAAthira PharmaN/AN/AN/AN/A$1.16 per shareN/ABCDABioCardia$60K168.35N/AN/A$0.18 per share10.83CHROChromocell TherapeuticsN/AN/AN/AN/A($1.65) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACGNAceragen-$23.36MN/A0.00∞N/AN/AN/AN/AN/AATHAAthira Pharma-$96.94M-$2.07N/AN/AN/AN/A-142.99%-106.40%7/30/2025 (Estimated)BCDABioCardia-$7.95M-$2.33N/AN/AN/AN/A-30,792.60%-223.06%8/12/2025 (Estimated)CHROChromocell Therapeutics-$7.38M-$1.24N/A∞N/AN/AN/A-453.90%N/ALatest ACGN, ATHA, BCDA, and CHRO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025BCDABioCardia-$0.39-$0.59-$0.20-$0.59N/AN/A5/9/2025Q1 2025ATHAAthira Pharma-$0.20-$0.23-$0.03-$0.23N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACGNAceragenN/AN/AN/AN/AN/AATHAAthira PharmaN/AN/AN/AN/AN/ABCDABioCardiaN/AN/AN/AN/AN/ACHROChromocell TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACGNAceragenN/AN/AN/AATHAAthira PharmaN/A7.267.26BCDABioCardiaN/A0.360.36CHROChromocell TherapeuticsN/A0.600.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACGNAceragen0.05%ATHAAthira Pharma57.12%BCDABioCardia20.57%CHROChromocell Therapeutics77.96%Insider OwnershipCompanyInsider OwnershipACGNAceragen26.45%ATHAAthira Pharma19.80%BCDABioCardia20.00%CHROChromocell Therapeutics16.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACGNAceragen268.42 million6.20 millionNot OptionableATHAAthira Pharma4039.04 million31.31 millionOptionableBCDABioCardia405.18 million4.14 millionOptionableCHROChromocell Therapeutics46.60 million5.04 millionN/AACGN, ATHA, BCDA, and CHRO HeadlinesRecent News About These CompaniesChannel Therapeutics Announces Reverse Common Stock Split in Conjunction with the Close of the Merger with Pelthos Therapeutics and Concurrent $50.1 Million Private PlacementJune 27 at 9:15 AM | globenewswire.comChromocell Therapeutics Co. (NYSE:CHRO) Sees Large Decline in Short InterestJune 20, 2025 | americanbankingnews.comChannel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing RulesMay 1, 2025 | globenewswire.comLigand subsidiaries, Chromocell Therapeutics to mergeApril 17, 2025 | markets.businessinsider.comChannel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on SuzetrigineDecember 20, 2024 | globenewswire.comChannel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block ModelDecember 18, 2024 | globenewswire.comChromocell Therapeutics Corp (CHRO)December 13, 2024 | investing.comChannel Therapeutics Corporation (CHRO)December 5, 2024 | finance.yahoo.comChromocell Announces Name Change to "Channel Therapeutics Corporation" and Provides Therapeutic Program UpdatesNovember 23, 2024 | stockhouse.comChromocell Therapeutics Rebrands to Focus on Pain TreatmentsNovember 22, 2024 | markets.businessinsider.comChromocell Announces Name Change to “Channel Therapeutics Corporation” and Provides Therapeutic Program UpdatesNovember 21, 2024 | markets.businessinsider.comChromocell Announces Name Change to “Channel Therapeutics Corporation†and Provides Therapeutic Program UpdatesNovember 21, 2024 | globenewswire.comChromocell Therapeutics Merges into Channel TherapeuticsNovember 20, 2024 | markets.businessinsider.comChromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical PainOctober 29, 2024 | globenewswire.comChromocell Announces Amendment to Stock Repurchase PlanOctober 24, 2024 | globenewswire.comChromocell to Participate in Life Sciences Investor Forum September 19thSeptember 16, 2024 | globenewswire.comChromocell Announces Stock Repurchase PlanAugust 7, 2024 | globenewswire.comChromocell to Participate in the Virtual Investor Lunch Break SeriesJuly 15, 2024 | globenewswire.comCHRO Stock Earnings: Chromocell Therapeutics Reported Results for Q1 2024May 20, 2024 | investorplace.comChromocell To Present at Alliance Global Partner's Healthcare Company Showcase on Tuesday, May 21, 2024May 13, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeValue vs Growth Ratio Hits Cycle Low—Top Value Picks to BuyBy Gabriel Osorio-Mazilli | June 30, 2025View Value vs Growth Ratio Hits Cycle Low—Top Value Picks to BuyRegional Bank Buybacks: 5 Institutions Making Big MovesBy Leo Miller | June 24, 2025View Regional Bank Buybacks: 5 Institutions Making Big MovesACGN, ATHA, BCDA, and CHRO Company DescriptionsAceragen NASDAQ:ACGNAceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States. Its clinical development pipeline includes ACG-701, which is in Phase 2 clinical trial for cystic fibrosis pulmonary exacerbations, as well as for melioidosis; and ACG-801 for farber disease. Aceragen, Inc. has a collaboration and option agreement with Scriptr Global, Inc. to identify, research, and develop gene therapy candidates for the treatment, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich's Ataxia. The company was formerly known as Idera Pharmaceuticals, Inc. and changed its name to Aceragen, Inc. in January 2023. Aceragen, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.Athira Pharma NASDAQ:ATHA$0.30 +0.01 (+2.37%) As of 04:00 PM EasternAthira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.BioCardia NASDAQ:BCDA$1.95 -0.20 (-9.30%) As of 04:00 PM EasternBioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.Chromocell Therapeutics NYSE:CHRO$1.26 -0.09 (-6.67%) As of 04:00 PM EasternChromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Alphabet’s Waymo and Services Beginning to Feel the Pressure? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
